TScan Therapeutics, Inc (TCRX) Fair Value & Analysis
Healthcare · US · Market cap $60.7M
TScan Therapeutics, Inc
TCRX · US
Fair value as of: Jul 19, 2026
From 1 valuation models · updated today
Share price +1.7% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.8400 – $2.52 · fair‑value band $0.4760 – $0.8925 · the $0.9150 price screens above the $0.7140 fair value. As of Jul 19, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
TScan Therapeutics, Inc (TCRX) currently trades at $0.9150, while our model-based Fair Value estimate is $0.7140, implying the stock looks roughly 22.0% overvalued today. We read business quality at 20/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at $9.1M. Revenue declined 54.8% year over year. It earns a return on equity of -81.0%. The balance sheet holds a net cash position of $58.3M. Fundamentals as of Jul 19, 2026
Our scenario range runs from $0.4760 (bear case) to $0.8925 (bull case); at $0.9150, the current price sits above that range. The share trades about 64% below its 52-week high and 8% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -15% fair-value upside, at -22%, TCRX screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 19, 2026. TTM = trailing twelve months.
About the company
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
TScan Therapeutics, Inc reported revenue of $10.3M in FY2025 versus $10.1M in FY2021, a compound +0.5%/yr. Reported net income was −$130M in FY2025.
Is TCRX fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $435.71 | $314.53 | -28% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$52.04 | R$46.95 | -10% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
| CSL Limited CSL | A$102.95 | A$126.79 | +23% |
| Celltrion, Inc 068270 | 168,500 KRW | 76,943 KRW | -54% |
| BioNTech SE B1NT34 | R$27.80 | R$23.67 | -15% |
| WuXi Biologics (Cayman) Inc 2269 | HK$29.70 | HK$26.76 | -10% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is TScan Therapeutics, Inc (TCRX) undervalued?
What is the fair value of TCRX?
What is the quality score of TCRX?
What is the revenue of TScan Therapeutics, Inc (TCRX)?
What is the net profit margin of TCRX?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Tell me when TScan Therapeutics, Inc reaches its Fair Value
Just your email, and we'll notify you when the price and Fair Value of TScan Therapeutics, Inc materially change. Free bonus: the monthly Top-25 report of the most undervalued quality stocks.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.